The Phase II clinical trial investigates Philogen's immunocytokines (i) L19IL2 (ii) L19TNF, and (iii) Nidlegy in combination with MSD's anti-PD-1 therapy, KEYTRUDA® (pembrolizumab) in stage III and IV
Philogen Announces Publication of a New Study in Collaboration with Google focused on Machine Learning models applied to DNA-Encoded Chemical Library Technology The collaboration has focused on the. | March 28, 2023
Philogen Provides Corporate Update | Comunicados | Edición USA efe.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from efe.com Daily Mail and Mail on Sunday newspapers.
Philogen Provides Corporate Update 211 out of 214 patients recruited in European Phase III trial investigating the neoadjuvant Nidlegy treatment of Stage IIIB/C melanoma, in line with expectations.Fibromun further